Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network.
Jan Hillert, Melinda Magyari, Per Soelberg Sørensen, Helmut Butzkueven, Anneke Van Der Welt, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Fabio Pellegrini, Robert Hyde, Leszek Stawiarz, Ali Manouchehrinia, Tim Spelman
Front Neurol | Frontiers Media SA | Published : 2021
Background: Although over a dozen disease modifying treatments (DMTs) are available for relapsing forms of multiple sclerosis (MS), treatment interruption, switching and discontinuation are common challenges. The objective of this study was to describe treatment interruption and discontinuation in the Big MS data network. Methods: We merged information on 269,822 treatment episodes in 110,326 patients from 1997 to 2016 from five clinical registries in this cohort study. Treatment stop was defined as a clinician recorded DMT end for any reason and included treatment interruptions, switching to alternate DMTs and long-term or permanent discontinuations. Results: The incidence of DMT stopping c..View full abstract